Gilead Sciences, Dr. Reddy's Laboratories
Dr. Reddy’s enters into licensing agreement with Gilead Sciences for HIV drug
Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.
Dr Reddy’s, Hetero ink royalty-free pact with Gilead
Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture Lenacapavir for HIV treatment in India and 120 LMICs, enhancing access for heavily treatment-experienced adults.
Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir
Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based
Dr. Reddy's inks licensing pact with Gilead to commercialise HIV drug
Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) infection in heavily treatment-experienced adults facing multi-drug resistant HIV-1.
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs.
Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir
Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries,
Dr Reddy’s Hetero ties up with Gilead Sciences for anti-HIV drug Lenacapavir
Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.
Gilead licenses HIV-prevention drug to generic drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries. WASHINGTON, United States — US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries.
Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug
Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries.
Dr. Reddy's Laboratories Share Price Live Updates: Dr. Reddy's Laboratories shows steady growth
Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...
Dr. Reddy's Laboratories rises Thursday, still underperforms market
Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.74% to 6,743.20 Indian rupees Thursday, on what proved to be an ...
Dr Reddy's Laboratories completes acquisition of Haleon's NRT portfolio
Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global ...
Announcements Updates: Announcement under Regulation 30 (LODR)-Updates on Acquisition
Stay updated with the Dr. Reddy's Laboratories Stock Liveblog, your one-stop destination for real-time information and ...
Business Line3d
Dr Reddy’s completes acquisition of Haleon Plc’s global portfolio of consumer healthcare brands in NRT
Dr Reddy’s Laboratories SA, Switzerland, an arm of Dr Reddy’s Laboratories, has completed the ...
money.rediff3d
Dr Reddy's Acquires Haleon's NRT Portfolio
Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, ...
Dr Reddy's completes acquisition of Haleon's NRT portfolio
Dr Reddy's Laboratories has acquired Haleon's global Nicotine Replacement Therapy (NRT) portfolio, excluding the US, for GBP ...